Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
News|Podcasts|October 27, 2026

The BioPharm Brief: Two Phase 3 ADC Wins and a TCR Bispecific in PRAME-High Tumors

BMS and SystImmune’s bispecific ADC iza-bren nearly doubles progression-free survival in EGFR-mutated lung cancer, GSK and Hansoh’s B7-H3 ADC Ris-Rez extends progression-free survival in relapsed osteosarcoma, and Immatics’ TCR bispecific IMA402 posts a 32% response rate in PRAME-high tumors.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry. Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry. Today, two antibody-drug conjugates deliver phase 3 wins in hard-to-treat cancers, and a T-cell receptor-based bispecific shows durable responses in melanoma.

First, Bristol Myers Squibb and SystImmune reported that izalontamab brengitecan, or iza-bren, nearly doubled progression-free survival in EGFR-mutated non-small cell lung cancer. Iza-bren is a bispecific ADC that targets both EGFR and HER3. In the phase 3 PANKU-Lung01 trial, patients whose disease had progressed after EGFR tyrosine kinase inhibitor therapy lived a median of 11.1 months without progression on iza-bren, compared with 5.7 months on platinum-based chemotherapy. Response rates were 60.2% vs 34.5%, and interstitial lung disease occurred in fewer than 1% of patients. Overall survival data are still immature, and the trial was conducted in mainland China. The drug holds FDA breakthrough therapy designation in this setting.

Next, GSK and Hansoh reported phase 3 results for risvutatug rezetecan, or Ris-Rez, a B7-H3-targeted ADC in relapsed osteosarcoma, a bone cancer that mainly affects children and young adults. In the ARTEMIS-011 trial in China, patients who had already received at least 2 prior therapies lived a median of 5.5 months without progression on Ris-Rez, compared with 1.4 months on chemotherapy, a 67% reduction in the risk of progression or death. Serious treatment-related side effects were common, occurring in 93% of patients on Ris-Rez vs 83% on chemotherapy. Hansoh plans to file in China, while GSK continues a global sarcoma trial.

And Immatics presented phase 1b data for IMA402, a T-cell receptor-based bispecific that targets the cancer antigen PRAME. Because PRAME sits inside cancer cells, conventional antibodies can’t reach it. IMA402 instead recognizes PRAME fragments displayed on the cell surface and recruits T cells to attack. In patients with high PRAME expression, 32% had a confirmed response. In PRAME-high melanoma, responses lasted a median of 12.5 months, and 91% of patients treated in the recommended dose range were alive at one year. Side effects were mostly transient and low grade, though the data are preliminary and come from an uncontrolled study.

That’s today’s BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key takeaways

  • Iza-bren: The EGFR×HER3 bispecific ADC nearly doubled progression-free survival over chemotherapy in EGFR-mutated NSCLC after TKI failure.
  • Ris-Rez: The B7-H3 ADC cut the risk of progression or death by 67% in relapsed osteosarcoma, but with frequent serious side effects.
  • IMA402: The PRAME-targeted TCR bispecific produced durable responses in PRAME-high melanoma, with 91% one-year survival at the recommended dose.

Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.